SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3,595.24 |
| Enterprise Value ($M) | 3,798.44 |
| Book Value ($M) | 152.70 |
| Book Value / Share | 2.48 |
| Price / Book | 23.55 |
| NCAV ($M) | 129.47 |
| NCAV / Share | 2.11 |
| Price / NCAV | 27.77 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.97 |
| Return on Assets (ROA) | -0.73 |
| Return on Equity (ROE) | -1.31 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.34 |
| Current Ratio | 3.49 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 340.34 |
| Assets | 363.57 |
| Liabilities | 210.88 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Perceptive Advisors Llc | 8.60 | 5.67 | |
| 13G/A | Ra Capital Management, L.p. | 9.95 | 14.15 | |
| 13G/A | Goldman Sachs Group Inc | 6.40 | -22.16 | |
| 13G/A | Primecap Management Co/ca/ | 11.81 | -10.38 | |
| 13D/A | New Enterprise Associates 13 Lp | |||
| 13G/A | Baker Bros. Advisors Lp | 10.80 | 0.69 | |
| 13G | Vanguard Group Inc | 5.46 | ||
| 13G/A | BlackRock, Inc. | 10.70 | 1.38 | |
| 13G/A | State Street Corp | 3.73 | -30.64 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| ‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 110,684 | 397,723 | 27.83 | |
| 137,670 | 528,059 | 26.07 | |
| 84,046 | 587,316 | 14.31 | |
| 91,776 | 374,409 | 24.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RNA – Avidity Biosciences, Inc. | RNAC – Cartesian Therapeutics, Inc. |
| RVNC – Revance Therapeutics, Inc. | SAGE – Sage Therapeutics, Inc. |
| SCYX – SCYNEXIS, Inc. |
Financial data and stock pages provided by
Fintel.io